Biotech company Sonnet BioTherapeutics enters into an $888 million merger agreement, concurrent with the introduction of their strategic HYPE Treasury plan.
In a significant shift, Sonnet BioTherapeutics Holdings, Inc. and Rorschach I LLC have merged to form a new publicly traded entity called Hyperliquid Strategies Inc. (HSI), valued at approximately $888 million. This strategic pivot marks Sonnet BioTherapeutics' move from biotech to cryptocurrency treasury management, centred around the HYPE token, the native currency of the Hyperliquid Layer-1 blockchain.
Hyperliquid Strategies Inc. will hold approximately 12.6 million HYPE tokens, valued around $583 million based on recent market prices, and possess a minimum of $305 million in cash reserves. This cash component will be actively used to purchase additional HYPE tokens, establishing one of the largest strategic reserves of this token.
The focus of Hyperliquid Strategies will be on managing and holding HYPE token reserves, positioning itself as a significant player in the crypto asset management space. This move offers investors direct exposure to HYPE and related crypto assets via a Nasdaq-listed vehicle.
Post-merger, Sonnet BioTherapeutics will become a wholly owned subsidiary of HSI. It will maintain some biotech operations, particularly continuing development of its biotech program, SON-1010, with support from capital raised through the merger.
The deal attracted a consortium of prominent crypto-focused and institutional investors, including Paradigm, Galaxy Digital, Pantera Capital, Republic Digital, D1 Capital, and 683 Capital.
The board and executive leadership of Hyperliquid Strategies have been refreshed. Bob Diamond (Co-founder and CEO of Atlas) has been named Chairman, and David Schamis (CIO and Co-founder of Atlas) has been appointed CEO of Hyperliquid Strategies. New board members are expected to include Eric Rosengren, former President of the Boston Fed, alongside existing independent directors from Sonnet.
Upon closing of the transactions, Bob Diamond will become Chairman of the Board of Hyperliquid Strategies. David Schamis will become the CEO of Hyperliquid Strategies, Inc. (HSI). The company will continue trading on the Nasdaq Capital Market under a new ticker symbol once the merger closes, anticipated in the second half of 2025 after regulatory approval and shareholder consent.
Matt Huang, Co-founder of Paradigm, views Hyperliquid as a crypto project with strong fundamentals, including strong core contributors, high product quality, and meteoric growth. Bob Diamond believes Hyperliquid Strategies will be well-positioned to maximize opportunities due to its unique team of investors and operators with deep, relevant crypto and financial services experience.
Sources: [1] Hyperliquid Strategies Press Release [2] Sonnet BioTherapeutics Press Release [3] Atlas Merger Announcement [4] CoinDesk Article on Hyperliquid Strategies Merger
Hyperliquid Strategies Inc.'s focus will expand to include finance and technology, as it manages and holds HYPE tokens, a component of the Hyperliquid Layer-1 blockchain. This new endeavor will allow for investment in technology-based assets, positioning Hyperliquid Strategies as a significant player in both the crypto asset management and technology sectors.
In the wake of the merger, Hyperliquid Strategies Inc. (HSI) will maintain connections to the business world through Sonnet BioTherapeutics, a subsidiary that will continue its biotech operations, including the development of SON-1010, while also exploring potential synergies with technology and finance.
